Is pulmonary vascular remodeling an intermediate link between hyperglycemia and adverse outcomes in patients with idiopathic pulmonary arterial hypertension? Insights from a multi-center cohort study

被引:0
|
作者
Zhang, Sicheng [1 ]
Gao, Luyang [1 ]
Li, Sicong [1 ]
Luo, Manqing [2 ]
Xi, Qunying [3 ]
Lin, Ping [4 ]
Zhao, Zhihui [1 ]
Zhao, Qing [1 ]
Yang, Tao [1 ]
Zeng, Qixian [1 ]
Huang, Zhihua [1 ]
Li, Xin [1 ]
Duan, Anqi [1 ]
Wang, Yijia [1 ]
Luo, Qin [1 ]
Guo, Yansong [2 ]
Liu, Zhihong [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Fuwai Hosp, Ctr Resp & Pulm Vasc Dis, 167,Beilishi Rd, Beijing 100037, Peoples R China
[2] Fuzhou Univ, Fujian Med Univ, Fujian Prov Hosp, Dept Cardiol,Affiliated Prov Hosp,Shengli Clin Med, 134,East St, Fuzhou 350001, Fujian, Peoples R China
[3] Chinese Acad Med Sci, Fuwai Hosp, Ctr Pulm Vasc Dis, Shenzhen, Peoples R China
[4] Fujian Med Univ, Hosp Joint Logist Support Force 900, Dept Pulm & Crit Care Med, Fuzhou, Peoples R China
关键词
Idiopathic pulmonary arterial hypertension; Stress hyperglycemia ratio; Admission blood glucose; Hemoglobin A1c; Outcomes; Mediation; ENDOTHELIAL GROWTH-FACTOR; CRITICALLY-ILL PATIENTS; STRESS-HYPERGLYCEMIA; PREDICTING SURVIVAL; HIGH GLUCOSE; RISK; MORTALITY; EXPRESSION; DIAGNOSIS; MARKER;
D O I
10.1186/s12933-024-02476-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Hyperglycemia upon admission is associated with poor prognosis of many cardiovascular diseases. However, the relationship of stress hyperglycemia ratio (SHR), admission blood glucose (ABG), and hemoglobin A1c (HbA1c) with pulmonary hypertension has not been reported. This study aimed to explore the association of hyperglycemia indices with disease severity and long-term adverse outcomes in patients with idiopathic pulmonary arterial hypertension (IPAH). Methods This multi-center cohort study included 625 consecutive patients diagnosed with or treated for IPAH between January 2015 and June 2023. SHR was calculated using the followings: ABG (mmol/L)/(1.59 x HbA1c [%] - 2.59). The primary endpoint was defined as clinical worsening events. Multivariable Cox regression and restricted cubic spline analyses were employed to evaluate the association of SHR, ABG, and HbA1c with endpoint events. The mediating effect of pulmonary hemodynamics was evaluated to investigate the potential mechanism between hyperglycemia and clinical outcomes. Results During a mean follow-up period of 3.8 years, 219 (35.0%) patients experienced all-cause death or clinical worsening events. Hyperglycemia indices correlated with well-validated variables that reflected the severity of IPAH, such as the World Health Organization functional class, 6-min walk distance, and N-terminal pro-brain natriuretic peptide levels. Multivariable Cox regression analyses indicated that SHR (hazard ratio [HR] 1.328, 95% confidence intervals [CI]: 1.185, 1.489 per 0.1-unit increment, P < 0.001) and ABG (HR 1.317, 95% CI: 1.134, 1.529 per 1.0-unit increment, P < 0.001) were independent predictors of primary endpoint events. Mediation analysis indicated that pulmonary vascular resistance mediated 5.65% and 14.62% of the associations between SHR and ABG and clinical worsening events, respectively. The addition of SHR significantly improved reclassification, discrimination ability, and model fit beyond the clinical risk prediction model. Conclusions SHR is positively associated with clinical worsening in patients with IPAH. The association appeared to be partially mediated through the pathway of pulmonary vascular remodeling, indicating that SHR may serve as a valuable indicator for providing additional risk information.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] THE PULMONARY VASCULAR RESISTANCE AND PULMONARY VASCULAR RESISTANCE TO SYSTEMIC RESISTANCE RATIO BUT NOT DIASTOLIC PULMONARY GRADIENT, MAY PREDICT SURVIVAL IN PATIENTS WITH PULMONARY HYPERTENSION: INSIGHTS FROM A SINGLE-CENTER STUDY
    Kaymaz, Cihangir
    Ozturk, Selcuk
    Akbal, Ozgur Y.
    Poci, Nertila
    Aktemur, Tugba
    Yilmaz, Fatih
    Tokgoz, Hacer
    Turkday, Sevim
    Hakgor, Aykun
    Ozdemir, Nihal
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (10) : A1562 - A1562
  • [22] BASELINE CHARACTERISTICS AND RISK FACTORS OF SLE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION: A MULTI-CENTER STUDY IN CHINA
    Qian, J.
    Li, M.
    Wang, Q.
    Zhao, J.
    Tian, Z.
    Wei, W.
    Zhang, X.
    Zuo, X.
    Zhang, M.
    Zhu, P.
    Ye, S.
    Zhang, W.
    Zheng, Y.
    Qi, W.
    Li, Y.
    Zhang, Z.
    Ding, F.
    Gu, J.
    Zeng, X.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (04) : S25 - S26
  • [23] What's in a side effect? The association between pulmonary vasodilator adverse drug events and clinical outcomes in patients with pulmonary arterial hypertension
    Leary, Peter J.
    Kang, Suhyun
    Kolb, Todd M.
    Maron, Bradley A.
    Ralph, David D.
    Rao, Youlan
    Tedford, Ryan J.
    Zamanian, Roham T.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 240 : 386 - 391
  • [24] ASSOCIATION BETWEEN ADVERSE RIGHT ATRIAL REMODELING AND INCIDENT ATRIAL FIBRILLATION AND ATRIAL FLUTTER IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
    Worapongsatitaya, Pitchaya
    Mohama, Danny A.
    Kazmirczak, Luis Felipe N.
    Prins, Kurt
    Thenappan, Thenappan
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 1918 - 1918
  • [25] Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study (vol 8, pg 873, 2020)
    Maron, Bradley A.
    Brittain, Evan L.
    Hess, Edward
    Waldo, Stephen W.
    Baron, Anna E.
    Huang, Shi
    Goldstein, Ronald H.
    Assad, Tufik
    Wertheim, Bradley M.
    Alba, George A.
    Leopold, Jane A.
    Olschewski, Horst
    Galie, Nazzareno
    Simonneau, Gerald
    Kovacs, Gabor
    Tedford, Ryan J.
    Humbert, Marc
    Choudhary, Gaurav
    LANCET RESPIRATORY MEDICINE, 2021, 9 (03): : E29 - E29
  • [26] Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular–Pulmonary Arterial Coupling
    Irina N. Taran
    Anna A. Belevskaya
    Marina A. Saidova
    Tamila V. Martynyuk
    Irina E. Chazova
    Lung, 2018, 196 : 745 - 753
  • [27] Increased serum PCSK9 in patients with idiopathic pulmonary arterial hypertension: insights from inflammatory cytokines
    Zhong, Dong-Xiang
    Zhang, Yuan
    Jin, Qi
    Zhang, Xiao-Chun
    Zhang, Feng
    Chen, Dan-Dan
    Guan, Li-Hua
    Zhou, Da-Xin
    Ge, Jun-Bo
    PULMONARY CIRCULATION, 2021, 11 (04)
  • [28] Idiopathic pulmonary arterial hypertension patients with a high H2FPEF-score: Insights from the Amsterdam UMC PAH-cohort
    Kianzad, Azar
    van Wezenbeek, Jessie
    Celant, Lucas R.
    Oosterveer, Frank P. T.
    Noordegraaf, Anton Vonk
    Meijboom, Lilian J.
    de Man, Frances S.
    Bogaard, Harm Jan
    Handoko, M. Louis
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2022, 41 (08): : 1075 - 1085
  • [29] Outcomes of Atrioseptostomy with Stenting in Patients with Pulmonary Arterial Hypertension from a Large Single-Institution Cohort
    Gorbachevsky, Sergey V.
    Shmalts, Anton A.
    Dadabaev, Gulomjon M.
    Nishonov, Nasirullo A.
    Pursanov, Manolis G.
    Shvartz, Vladimir A.
    Zaets, Sergey B.
    DIAGNOSTICS, 2020, 10 (09)
  • [30] Imaging Signatures in Idiopathic Pulmonary Fibrosis (IS-IPF) Study from Multi-Center Multidisciplinary Experiences in ILD
    Dai, D.
    Weigt, S.
    Goldin, J.
    Song, J.
    Pourzand, L.
    Oh, J.
    Choe, J.
    Abtin, F.
    Brown, M.
    Kim, G. H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)